Keywords: Apoptosis; apoptosis pathways; cancer; cancer development; cancer treatment
Apoptosis is one of the most acceptable mechanisms
for anticancer activity in cancer cells. The regulatory
mechanisms of apoptosis are very complex. Reactive
oxygen species, caspase activation, tumor necrosing
factor (TNF), protein kinase, and mitochondrial pathway
form the basis of apoptosis.[
What Is Cancer?
Cancer is a complex disease caused by uncontrolled
division and proliferation of cells and under the influence
of genetic and environmental conditions. Cancer
is also a personal disease, although there are more than
100 known types of cancer and standard approaches
have been developed for certain types of cancers.
Cancer is the uncontrolled division, proliferation, and
accumulation of cells in an organism. It can affect a single
organ as well as spread to distant organs and show
its effect.[
What Is Apoptosis?
Apoptosis; it is programmed cell death, which is an
important cell growth control component that ensures
the elimination of cells that are not needed, whose
functions are impaired, that have completed their biological
task or are damaged after exposure to a certain
stimulus.[
There are two pathways in apoptosis: Extrinsic
pathway and intrinsic pathway.[
Extrinsic Pathway (Receptor Pathway)
Instrinsic Pathway (Mitochondrial Pathway)
Apoptosis and Cancer Relationship
The irregularity of apoptotic pathways not only promotes
tumor formation but can also make the cancer
cell resistant to treatment. Therefore, irregularity of
apoptosis is an important cancer symptom.[
As with B cell lymphoma, decreased apoptosis in
some tumors can cause tumor development. In general,
an increase in apoptosis is observed due to the increase
in proliferation in tumor tissue.[
Disorders in programmed cell death (apoptosis)
mechanisms play important roles in tumor pathogenesis.
Apoptosis allows neoplastic cells to survive over
their intended lifespan, reduces the need for exogenous
survival factors, and provides protection from oxidative
stress and hypoxia as the tumor mass expands.[
In chronic lymphocytic leukemia, IL-4 levels increase,
excessive production of Bcl-2 occurs, and the
life span of malignant B cells is prolonged. Two antiapoptotic
cytokines IL-4 and IL-10 are released in thyroid
carcinoma cells and contribute to cancer development.[
p53 and Cancer
Regulation of apoptosis in humans is a process that
starts with p53 and continues up to caspases. Cell life
is prolonged when p53, which works as a tumor suppressor
gene, is mutated or absent. Cell damage caused
by genotoxic events activates a transcription regulator
gene, p53. After the p53 protein product binds directly
to DNA and recognizes the damage, it either induces
cell cycle arrest in G1, gaining time for repair, or directs
apoptosis if the damage is greater. In addition, p53 is
thought to regulate the ratios of Bax/Bax, Bax/Bcl-2,
and Bcl-2/Bcl-2 groups.[
Caspases and Cancer
Initiator caspases transmit death signals initiated by
apoptotic stimulation to effector caspases. Effector caspases,
on the other hand, break down related proteins
and cause the formation of apoptotic cell morphology.
Defects in the caspase can contribute to autoimmune
diseases, cancer, and the formation of some neurological
disorders.[
IAPs and Cancer
IAPs are a group of structurally and functionally
similar proteins that regulate apoptosis, cytokinesis,
and signal transduction. They are characterized by the
presence of a baculovirus IAP repeat (BIR) protein domain.[
Irregular IAP expression has been reported in many
cancers. For example, Lopes et al.,[
Survivin, another IAP, has been reported to
be overexpressed in various cancers. Small et
al.,[
Survivin has been found to be overexpressed in
non-small cell lung carcinomas (NSCLC) in conjunction
with XIAP. It has been concluded that Survivin
overexpression in most NSCLCs is accompanied by excess
or upregulated expression of XIAP.[
Carcinogenesis by Intrinsic Apoptosis Pathway
Mutations
Antiapoptotic proteins block the death signal by
partially antagonizing the effects of Bax/Bak through
known mechanisms. Furthermore, antiapoptotic proteins
prevent Bax/Bak activation by sequestrating/inhibiting
BH3-only proteins "activator" and/or directly
inhibiting Bax/Bak activation.[
Antiapoptotic proteins (e.g., Bcl-2, Bcl-xL, Bcl-W,
Mcl-1, and Bfl-1/A1, which exhibit sequence homology
in all BH1-BH4 domains) increase cell survival,
while proapoptotic proteins are receptor, endoplasmic
reticulum (ER), or mitochondria. ER mediates stressinduced
apoptosis. The next group contains proteins
that contain the multi-domain or BH3- only. The first
consists of Bax and Bak, which are necessary for apoptosis.[
The central role played by Bax/Bak in apoptosis is
supported by studies that BH3-only proteins do not induce
apoptosis in cells with Bax/Bak deficiency.[
Carcinogenesis by Extrinsic Apoptosis Pathway
Mutations
Another molecule, c-FLIP, which regulates caspase-
8 activation, is c-FLIP (L), which are long IL-1Β
converting enzyme inhibitor proteins similar to cellular
FADD. Another molecule, c-FLIP, which regulates
caspase-8 activation, is c-FLIP (L), which are long interleukin-
1 beta converting enzyme inhibitor proteins
similar to cellular FADD.[
Melanoma, hepatocellular carcinoma, non-small
cell lung carcinoma[
The high expression of C-FLIP blocks caspase-8
and makes cells resistant to cell receptor-mediated
apoptosis.[
Mice-based studies on the use of neutralizing
antibodies and Fc-fusion proteins as well as genetic
changes in genes encoding death ligands or their
receptors, found that death ligands and the genes
encoding them play important roles in tumor suppression by cellular immune mechanisms. aFas ligand
(FasL) is important for CTL-mediated killing
of some tumor targets, and TRAIL (Apo2 ligand) is
critical for NK-mediated tumor suppression. Some
tumor cells resist the death receptor pathway"s response
to FasL produced by T cells to avoid immune
damage. Many tumor cells show intrinsic resistance
to TRAIL. This directly sequesters Fas of ligand or
expression Fas ligand on the surface of tumor cells.
This is downregulation of the Fas receptor, a dysfunctional
Fas receptor, and it creates the secretion
of high levels of Fas receptor.[
Apoptosis and Cancer Treatment
Apoptosis and Cancer Theratment targets apoptosis
via receptor-chondrial-mediated. Many drugs are
used in cancer treatment today to kill cells. Disruption
of mitochondrial membrane potential, cytochrome c
release, and activation of different caspases have been
identified following treatment of cells with different
chemotherapeutic agents (Table
Tumor selective expression of proapoptotic Bax by
adenoviral gene transfer leads to selective toxicity in
tumor cells.[
Bortezomib has a sensitive effect on apoptosis induced
by NF-κB suppression by downregulated Bcl-2.
[
Cancer has been a common problem in humans and
animals throughout the known history. The earliest known records about cancer date back to 3000 BC.
The word cancer is derived from the words "canker" or
"carcinos," which means crab in Latin. The term tumor
was first used by Hippocrates in the 3rd century BC because
it compared the swollen veins around the tumor
to the legs of a crab, and the term "oncos," which means
swelling, was used.[
Apoptosis is a word formed by the combination of ancient
Greek apo (separate) and ptosis (fall) and used by Homeres to describe leaf fall in autumn. For this reason,
it is the type of cell death that occurs when some
cells dry up like autumn leaves and leave the body and
make room for the cells coming from behind. It was
named "apoptosis" with the suggestion of the classical
Greek historian James Cormack.[
This pathway is stimulated by the tumor necrosis
factor-alpha (TNF-alpha) family, which binds to the
CD95 ligand (Fas ligand=CD95L) by extracellular
signals. This binding causes the formation of deathinducing
signal complex (DISC) by causing conformational
changes independent of ATP at the receptor.
With the CD95 adapter molecule Fas receptor-associated
measurement unit (FADD), FADD also combines
with procaspase-8 and procaspase-10 to form the DISC
complex. Separation of small and large subunits is not
required for activation. The next step is activation of
procaspase-8, causing proteolysis from caspase-3 to
separate from the small subunit, thereby activating the
enzyme. This pathway combines with the mitochondrial
pathway through the caspase-3 activation, thereby
strengthening the apoptosis signal. Cellular FLICE-inhibiting
proteins (cFLIP, cFLIPL, cFLIPs) can combine
with DISC to inhibit the activation of caspase-8 and 10,
preventing apoptosis.[
Unlike this pathway death receptor pathway, it can be
induced by both extracellular signals (growth factor
or hormone deficiency, ultraviolet beam, and various
cytokines) and intracellular signals that cause DNA
damage. While the intracellular signal stimulates the
proapoptotic members of the Bcl-2 family, it migrates
to the mitochondria, while the proapoptotic members
settle on the outer mitochondrial membrane and form
pores (mitochondrial passages) here. These pores allow
cytochrome-c separation from mitochondria. Cytochrome
c; Combining with apaf-1, ATP, dATP, and procaspase-9, the apoptosome activates caspase-3.
Although their beginnings are different, they both result
in caspase-3 activation in both pathways. Furthermore,
apoptosis-inducing factor (AIF) from mitochondria is
released in molecules such as G, Smac/DIABLO, and
Omi/HtrA2. Endonuclease G and AIF, while inducing
DNA fragmentation, Smac/DIABLO, and Omi/HtrA2
neutralize apoptosis-inhibiting protein (ınhibitor of
apoptosis proteins [IAPs]). Molecules such as Smac/
DIABLO and Omi/HtrA2 are located in the intermembrane
region of the mitochondria, such as cytochrome
c. Smac/DIABLO and Omi/HtrA2 have many similar
aspects. However, while Smac/DIABLO is not found in
the heart and detected in the brain, on the other hand,
there is a widespread distribution of Omi/HtrA2.[
In cancer, an important disease associated with apoptosis,
the balance between cell proliferation and cell
death is disrupted, and cells are unable to receive death
signals to cause apoptosis. This can cause problems at
any step of the apoptotic pathways. Better understanding
of the molecular events regulating apoptosis mechanisms
enables the creation or development of new
treatment options for the activation or inhibition of the
target molecules in these pathways.[
The first gene therapy product used in cancer treatment
is Gendicine, which is specifically designed to express
p53 (rAd-p53). In a study conducted on patients
with oral cancer, it has been shown that administration
of rAd-p53 infusion together with chemotherapy significantly
increases the survival rate in patients. Apart
from that, it has been stated that it is used effectively
in hepatocellular carcinoma, tongue cancer, and some
other types of cancer.[
Although the mechanism of apoptosis is not fully explained,
the most important event associated with
apoptosis is the activation of caspases.[
IAP (inhibitors of apoptosis), a family of caspase inhibitors,
selectively inhibit caspases. Thus, they stop the
apoptotic mechanism. These inhibitors are expressed
by many malignant cells. IAPs can also stop apoptosis
by affecting the cell cycle.[
The intrinsic apoptosis pathway is one of the most important
pathways for apoptosis induction. Therefore,
disrupting this pathway is an effective way of preventing
apoptosis. Bcl-2 family proteins (c=24 in humans)
are central regulators of the intrinsic pathway, either
suppressing or promoting changes in mitochondrial
membrane permeability required for the release of
cyt-c and other apoptogenic proteins.[
It is activated in vivo by TNF family ligands that bind
DD-containing receptors, which means that DED-containing
caspases lead to its activation. "Death ligands"
are expressed on CTLs, NK cells, and other immunerelated
cells (activated monocytes/macrophages and
nitrite cells) and are used as weapons for destroying
transformed cells.[
Cancer-related defects in apoptosis play a role in resistance
to treatment with traditional treatments such
as chemotherapy and radiotherapy, increasing the cell
death threshold, thus requiring higher doses of tumoricidal
agents.[
Peer-review: Externally peer-reviewed.
Conflict of Interest: Authors declare no conflict of interest.
Financial Support: No financial support has been used for this study.